First case of cutaneous sarcoidosis within tattoos under durvalumab

Int J Dermatol. 2019 Sep;58(9):e168-e170. doi: 10.1111/ijd.14484. Epub 2019 Jun 4.

Authors

Perrine M Rousseau¹, Judith Raimbourg², Marie Robert², Delphine Dansette³, Brigitte Dréno¹, Lucie Peuvrel^{1

2}; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments

Affiliations

¹ Department of Dermatology, CHU Nantes, Université Nantes, Nantes, France.
² Department of Medical Oncology, ICO Gauducheau, Nantes, France.
³ Department of Pathology, CHU Nantes, Université Nantes, Nantes, France.

PMID: 31162632
DOI: 10.1111/ijd.14484

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adrenal Gland Neoplasms / drug therapy
Adrenal Gland Neoplasms / secondary
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Biopsy
Brain Neoplasms / drug therapy
Brain Neoplasms / secondary
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Male
Middle Aged
Sarcoidosis / diagnosis*
Sarcoidosis / etiology
Sarcoidosis / pathology
Skin / pathology
Tattooing / adverse effects*

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
durvalumab